Mood and Sexual Function in Polycystic Ovary Syndrome

Onno E. Janssen; Susanne Hahn; Susanne Tan; Sven Benson; Sigrid Elsenbruch

doi:10.1055/s-2007-992924

Seminars in Reproductive Medicine, Table of Contents

Semin Reprod Med 2008; 26(1): 045-052
DOI: 10.1055/s-2007-992924

Mood and Sexual Function in Polycystic Ovary Syndrome

Onno E. Janssen¹ , Susanne Hahn² , Susanne Tan³ , Sven Benson⁴ , Sigrid Elsenbruch⁴

¹Division of Endocrinology, Metabolism and Molecular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois
²Praxis für Endokrinologie, Wuppertal, Germany
³Division of Endocrinology, Department of Medicine, University Hospital of Essen Medical School, Essen, Germany
⁴Institute of Medical Psychology, University Hospital of Essen Medical School, Essen, Germany

Abstract

ABSTRACT

Women with polycystic ovary syndrome (PCOS) fail to conform with societal norms for outer appearance. Many PCOS patients thus feel stigmatized in the sense of a loss of “feminine identity.” In addition to somatic impairment, mood disturbances such as depression and limitations in emotional well-being, quality of life, and life satisfaction, the diagnosis of PCOS also has a negative impact on sexual self-worth and sexual satisfaction. Both obesity and hirsutism are major determinants of the physical component of quality of life in affected women. However, its psychological aspect appears to be inherent and specific for PCOS. Confirmation of the diagnosis and provision of detailed information to affected women, together with the availability of interdisciplinary treatment aimed at improving PCOS-related symptoms, such as hirsutism, obesity, menstrual irregularity, and infertility, will also reduce psychological distress and improve sexual self-worth. New treatment options, including insulin sensitizers, psychological counseling, and participation in a PCOS support group, are likely to further improve life satisfaction and coping of affected women.

KEYWORDS

Polycystic ovary syndrome - quality of life - psychological disturbances - sexual satisfaction - hirsutism - obesity - hyperandrogenism

Full Text

References

REFERENCES

1 WHO .Development and Constitution of the W.H.O. Geneva. Switzerlandm; United Nations 1947
2 WHO Division of Mental Health .WHO-QOL Study Protocol: The Development of the World Health Organization Quality of Life Assessment Instrument. Geneva, Switzerland; United Nations 1993
3 Ferrell B, Grant M, Padilla G, Vemuri S, Rhiner M. The experience of pain and perceptions of quality of life: validation of a conceptual model. Hosp J. 1991; 7 9-24
4 Diamanti-Kandarakis E, Kouli C R, Bergiele A T et al.. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab. 1999; 84 4006-4011
5 Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000; 85 2434-2438
6 Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004; 89 2745-2749
7 Ehrmann D A. Polycystic ovary syndrome. N Engl J Med. 2005; 352 1223-1236
8 Hahn S, Tan S, Elsenbruch S et al.. Clinical and biochemical characterization of women with polycystic ovary syndrome in North Rhine-Westphalia. Horm Metab Res. 2005; 37 438-444
9 Elsenbruch S, Benson S, Hahn S et al.. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod. 2006; 21 1092-1099
10 Avery J C, Braunack-Mayer A J. The information needs of women diagnosed with polycystic ovarian syndrome-implications for treatment and health outcomes. BMC Womens Health. 2007; 7 9
11 Ching H L, Burke V, Stuckey B G. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf). 2007; 66 373-379
12 Dunaif A, Thomas A. Current concepts in the polycystic ovary syndrome. Annu Rev Med. 2001; 52 401-419
13 Escobar-Morreale H F, Luque-Ramirez M, San Millan J L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev. 2005; 26 251-282
14 Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006; 91 781-785
15 Zawadski J K, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR Polycystic Ovary Syndrome. Boston; Blackwell Scientific 1992: 377-384
16 The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group . Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19 41-47
17 Himelein M J, Thatcher S S. Polycystic ovary syndrome and mental health: a review. Obstet Gynecol Surv. 2006; 61 723-732
18 Eggers S, Kirchengast S. The polycystic ovary syndrome-a medical condition but also an important psychosocial problem. Coll Antropol. 2001; 25 673-685
19 Kitzinger C, Willmott J. ‘The thief of womanhood’: women's experience of polycystic ovarian syndrome. Soc Sci Med. 2002; 54 349-361
20 Sills E S, Perloe M, Tucker M J, Kaplan C R, Genton M G, Schattman G L. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health. 2001; 1 3
21 Trent M E, Rich M, Austin S B, Gordon C M. Quality of life in adolescent girls with polycystic ovary syndrome. Arch Pediatr Adolesc Med. 2002; 156 556-560
22 Trent M, Austin S B, Rich M, Gordon C M. Overweight status of adolescent girls with polycystic ovary syndrome: body mass index as mediator of quality of life. Ambul Pediatr. 2005; 5 107-111
23 Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf). 2000; 52 595-600
24 Legro R S. Polycystic ovary syndrome and cardiovascular disease: a premature association?. Endocr Rev. 2003; 24 302-312
25 Cronin L, Guyatt G, Griffith L et al.. Development of a health-related quality-of-life questionnaire (PCOSQ) for women with polycystic ovary syndrome (PCOS). J Clin Endocrinol Metab. 1998; 83 1976-1987
26 Jones G L, Benes K, Clark T L et al.. The Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (PCOSQ): a validation. Hum Reprod. 2004; 19 371-377
27 Coffey S, Bano G, Mason H D. Health-related quality of life in women with polycystic ovary syndrome: a comparison with the general population using the Polycystic Ovary Syndrome Questionnaire (PCOSQ) and the Short Form-36 (SF-36). Gynecol Endocrinol. 2006; 22 80-86
28 Guyatt G, Weaver B, Cronin L, Dooley J A, Azziz R. Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated. J Clin Epidemiol. 2004; 57 1279-1287
29 Schmid J, Kirchengast S, Vytiska-Binstorfer E, Huber J. Infertility caused by PCOS-health-related quality of life among Austrian and Moslem immigrant women in Austria. Hum Reprod. 2004; 19 2251-2257
30 Pekhlivanov B, Kolarov G, Kavurdzhikova S, Stoikov S. Determinants of health related quality of life in women with polycystic ovary syndrome [in Bulgarian]. Akush Ginekol (Sofiia). 2006; 45 29-34
31 Zung W WA. Self-Rating Depression Scale. Arch Gen Psychiatry. 1965; 12 63-70
32 Barnard L, Ferriday D, Guenther N, Strauss B, Balen A H, Dye L. Quality of life and psychological well being in polycystic ovary syndrome. Hum Reprod. 2007; 22 2279-2286
33 Elsenbruch S, Hahn S, Kowalsky D et al.. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003; 88 5801-5807
34 Ware Jr J E, Sherbourne C D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992; 30 473-483
35 McHorney C A, Ware Jr J E, Raczek A E. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993; 31 247-263
36 Schmitz N, Hartkamp N, Kiuse J, Franke G H, Reister G, Tress W. The Symptom Check-List-90-R (SCL-90-R): a German validation study. Qual Life Res. 2000; 9 185-193
37 Derogatis L R, Rickels K, Rock A F. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry. 1976; 128 280-289
38 Henrich G, Herschbach P. Questions on life satisfaction (FLZ) - A short questionnaire for assessing subjective quality of life. Eur J Psychol Assess. 2000; 16 150-159
39 Goldbeck L, Schmitz T G. Comparison of three generic questionnaires measuring quality of life in adolescents and adults with cystic fibrosis: the 36-item short form health survey, the quality of life profile for chronic diseases, and the questions on life satisfaction. Qual Life Res. 2001; 10 23-36
40 Sonino N, Fava G A, Mani E, Belluardo P, Boscaro M. Quality of life of hirsute women. Postgrad Med J. 1993; 69 186-189
41 Loo W J, Lanigan S W. Laser treatment improves quality of life of hirsute females. Clin Exp Dermatol. 2002; 27 439-441
42 Hahn S, Janssen O E, Tan S et al.. Clinical and psychological correlates of quality-of-life in polycystic ovary syndrome. Eur J Endocrinol. 2005; 153 853-860
43 Keegan A, Liao L M, Boyle M. ‘Hirsutism’: a psychological analysis. J Health Psychol. 2003; 8 327-345
44 Barth J H, Catalan J, Cherry C A, Day A. Psychological morbidity in women referred for treatment of hirsutism. J Psychosom Res. 1993; 37 615-619
45 Shulman L H, DeRogatis L, Spielvogel R, Miller J L, Rose L I. Serum androgens and depression in women with facial hirsutism. J Am Acad Dermatol. 1992; 27(2 Pt 1) 178-181
46 Coffey S, Mason H. The effect of polycystic ovary syndrome on health-related quality of life. Gynecol Endocrinol. 2003; 17 379-386
47 Klassen A F, Newton J N, Mallon E. Measuring quality of life in people referred for specialist care of acne: comparing generic and disease-specific measures. J Am Acad Dermatol. 2000; 43(2 Pt 1) 229-233
48 Mallon E, Newton J N, Klassen A, Stewart-Brown S L, Ryan T J, Finlay A Y. The quality of life in acne: a comparison with general medical conditions using generic questionnaires. Br J Dermatol. 1999; 140 672-676
49 Yazici K, Baz K, Yazici A E et al.. Disease-specific quality of life is associated with anxiety and depression in patients with acne. J Eur Acad Dermatol Venereol. 2004; 18 435-439
50 Dolte K S, Girman C J, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Development of a health-related quality of life questionnaire for women with androgenetic alopecia. Clin Exp Dermatol. 2000; 25 637-642
51 Girman C J, Hartmaier S, Roberts J, Bergfeld W, Waldstreicher J. Patient-perceived importance of negative effects of androgenetic alopecia in women. J Womens Health Gend Based Med. 1999; 8 1091-1095
52 Van Der Donk J, Hunfeld J A, Passchier J, Knegt-Junk K J, Nieboer C. Quality of life and maladjustment associated with hair loss in women with alopecia androgenetica. Soc Sci Med. 1994; 38 159-163
53 Paoletti A M, Floris S, Mannias M et al.. Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. J Clin Endocrinol Metab. 2001; 86 608-612
54 Weiner C L, Primeau M, Ehrmann D A. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004; 66 356-362
55 Goldstat R, Briganti E, Tran J, Wolfe R, Davis S R. Transdermal testosterone therapy improves well-being, mood, and sexual function in premenopausal women. Menopause. 2003; 10 390-398
56 Shifren J L, Braunstein G D, Simon J A et al.. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med. 2000; 343 682-688
57 Floter A, Nathorst-Boos J, Carlstrom K, von Schoultz B. Addition of testosterone to estrogen replacement therapy in oophorectomized women: effects on sexuality and well-being. Climacteric. 2002; 5 357-365
58 Sherwin B B, Gelfand M M, Brender W. Androgen enhances sexual motivation in females: a prospective, crossover study of sex steroid administration in the surgical menopause. Psychosom Med. 1985; 47 339-351
59 Paulson J D, Haarmann B S, Salerno R L, Asmar P. An investigation of the relationship between emotional maladjustment and infertility. Fertil Steril. 1988; 49 258-262
60 Trent M E, Rich M, Austin S B, Gordon C M. Fertility concerns and sexual behavior in adolescent girls with polycystic ovary syndrome. Implications for quality of life. J Pediatr Adolesc Gynecol. 2003; 16 33-37
61 Monga M, Alexandrescu B, Katz S E, Stein M, Ganiats T. Impact of infertility on quality of life, marital adjustment, and sexual function. Urology. 2004; 63 126-130
62 Wischmann T, Stammer H, Scherg H, Gerhard I, Verres R. Psychosocial characteristics of infertile couples: a study by the ‘Heidelberg Fertility Consultation Service’. Hum Reprod. 2001; 16 1753-1761
63 Ragni G, Mosconi P, Baldini M P et al.. Health-related quality of life and need for IVF in 1000 Italian infertile couples. Hum Reprod. 2005; 20 1286-1291
64 Himelein M J, Thatcher S S. Depression and body image among women with polycystic ovary syndrome. J Health Psychol. 2006; 11 613-625
65 Ardenti R, Campari C, Agazzi L, La Sala G B. Anxiety and perceptive functioning of infertile women during in-vitro fertilization: exploratory survey of an Italian sample. Hum Reprod. 1999; 14 3126-3132
66 Chiba H, Mori E, Morioka Y et al.. Stress of female infertility: relations to length of treatment. Gynecol Obstet Invest. 1997; 43 171-177
67 Guerra D, Llobera A, Veiga A, Barri P N. Psychiatric morbidity in couples attending a fertility service. Hum Reprod. 1998; 13 1733-1736
68 Oddens B J, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems-a comparative survey. Hum Reprod. 1999; 14 255-261
69 Boivin J, Takefman J E, Tulandi T, Brender W. Reactions to infertility based on extent of treatment failure. Fertil Steril. 1995; 63 801-807
70 Fekkes M, Buitendijk S E, Verrips G H et al.. Health-related quality of life in relation to gender and age in couples planning IVF treatment. Hum Reprod. 2003; 18 1536-1543
71 McCook J G, Reame N E, Thatcher S S. Health-related quality of life issues in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2005; 34 12-20
72 Stunkard A J, Faith M S, Allison K C. Depression and obesity. Biol Psychiatry. 2003; 54 330-337
73 Mannucci E, Ricca V, Barciulli E et al.. Quality of life and overweight: the obesity related well-being (Orwell 97) questionnaire. Addict Behav. 1999; 24 345-357
74 Swallen K C, Reither E N, Haas S A, Meier A M. Overweight, obesity, and health-related quality of life among adolescents: the National Longitudinal Study of Adolescent Health. Pediatrics. 2005; 115 340-347
75 Hashimoto D M, Schmid J, Martins F M et al.. The impact of the weight status on subjective symptomatology of the polycystic ovary syndrome: a cross-cultural comparison between Brazilian and Austrian women. Anthropol Anz. 2003; 61 297-310
76 Faith M S, Matz P E, Jorge M A. Obesity-depression associations in the population. J Psychosom Res. 2002; 53 935-942
77 Onyike C U, Crum R M, Lee H B, Lyketsos C G, Eaton W W. Is obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2003; 158 1139-1147
78 Derogatis L R, Rose L I, Shulman L H, Lazarus L A. Serum androgens and psychopathology in hirsute women. J Psychosom Obstet Gynaecol. 1993; 14 269-282
79 Cecchine R. Scrambled; a journey through polycystic ovarian syndrome. Available at: http://scrambledthewebsite.com , Accessed February 11, 2007
80 Matsunaga H, Sarai M. Elevated serum LH and androgens in affective disorder related to the menstrual cycle: with reference to polycystic ovary syndrome. Jpn J Psychiatry Neurol. 1993; 47 825-842
81 Bruce-Jones W, Zolese G, White P. Polycystic ovary syndrome and psychiatric morbidity. J Psychosom Obstet Gynaecol. 1993; 14 111-116
82 Dittmar M, Heintz A, Hardt J, Egle U T, Kahaly G J. Metabolic and psychosocial effects of minimal invasive gastric banding for morbid obesity. Metabolism. 2003; 52 1551-1557
83 Jalil R A, Manan W A, Bebakar W M, Halim R, Ooi G S, Othman R. Assessing changes in quality of life among obese participants in Kelantan, Malaysia. Asia Pac J Clin Nutr. 2004; 13(Suppl) S141
84 Mathus-Vliegen E M, de Weerd S, de Wit L T. Health-related quality-of-life in patients with morbid obesity after gastric banding for surgically induced weight loss. Surgery. 2004; 135 489-497
85 Ogden J, Clementi C, Aylwin S, Patel A. Exploring the impact of obesity surgery on patients' health status: a quantitative and qualitative study. Obes Surg. 2005; 15 266-272
86 Lord J M, Flight I H, Norman R J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev. 2003; 3 CD003053
87 Hahn S, Benson S, Elsenbruch S et al.. Metformin treatment of polycystic ovary syndrome improves health-related quality-of-life, emotional distress and sexuality. Hum Reprod. 2006; 21 1925-1934

Onno E JanssenM.D.

Raalandsweg 36

22559 Hamburg, Germany

Email: onno@onnojanssen.de